PLoS ONE:炎症基因表达调控或导致抑郁症与癌症患者存活率的相关性

2012-08-06 Beyond 生物谷

根据一项新的研究证实:抑郁症症状与癌症患者的生存时间较短相关。近日,得克萨斯大学MD安德森癌症中心研究人员在8月1日的PLoS ONE杂志上发表论文称:这种相关性可能是由于应激激素调节异常和炎症基因表达导致的。 肿瘤学和行为科学中心部门教授Lorenzo Cohen说:研究发现心理健康和社会福祉良好是可以影响生物过程以及影响癌症发展的。该研究还表明,心理健康筛查应该是标准治疗的一部分,因为这

根据一项新的研究证实:抑郁症症状与癌症患者的生存时间较短相关。近日,得克萨斯大学MD安德森癌症中心研究人员在8月1日的PLoS ONE杂志上发表论文称:这种相关性可能是由于应激激素调节异常和炎症基因表达导致的。

肿瘤学和行为科学中心部门教授Lorenzo Cohen说:研究发现心理健康和社会福祉良好是可以影响生物过程以及影响癌症发展的。该研究还表明,心理健康筛查应该是标准治疗的一部分,因为这是公认的可以帮助人们管理困扰的方法,即使在面对危及生命疾病的情况下。

在研究中,研究人员分析了超过217例新诊断肾细胞癌已经扩散五年的患者。参与人员回答了研究者的宗教和精神问题。他们还询问了他们的抑郁症症状、生活质量和应对技能等。患者也提供了血液样本,以及5个唾液样本,每天一次共三天。

研究人员使用唾液样本来跟踪患者的皮质醇、应激激素的全天变化情况,发现通常是在早晨高,之后会下降。在跟踪分析时,64%的患者已经死亡。这些患者被确诊后存活的平均时间为1.8年。

总的来说这项研究表明,23%的患者存在临床抑郁症。即使考虑其他疾病相关的危险因素后,研究者指出,抑郁症也是会导致存活时间较短。此外,研究表明体内皮质醇水平全天都高于正常水平也会降低癌症患者的生存。

使用15例存在抑郁症最显著的症状患者与抑郁症最温和患者的15个组织样本,研究人员进行全基因组分析,以确定是否忧郁症与癌症死亡的风险增加有关。他们发现调节细胞炎症的特定信号通路在抑郁症癌症患者表达水平明显提高,在这种相关性中起到了关键作用。

这项研究的作者得出结论:患者的心理健康和生存时间之间的联系与炎症基因表达调控相关。研究结果表明,现在能够确定一些可能的机理来解释抑郁症和生存之间的关联。虽然这项研究发现抑郁症和癌症存活率之间的关联,但它并不能证明两者之间的因果关系。

doi:10.1371/journal.pone.0042324
PMC:
PMID:

Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

Lorenzo Cohen1*, Steven W. Cole2, Anil K. Sood3, Sarah Prinsloo1, Clemens Kirschbaum4, Jesusa M. G. Arevalo2, et al.

Purpose

Evidence has supported the association between psychological factors and cancer biology; however, findings are equivocal on the role of psychosocial factors in cancer progression. This study generates a hypothesis of mechanistic variables by examining the clinical effects of psychosocial factors and cortisol dysregulation in patients with metastatic renal cell carcinoma (RCC) and examines associated activation of transcription control pathways.

Methods

Patients with metastatic RCC (n = 217) were prospectively enrolled in this study. Patients completed questionnaires (Centers for Epidemiologic Studies – Depression; SF-36 Health Status Survey; Duke Social Support Index; Coping Operations Preference Enquiry; organized and non-organized religious activity; and intrinsic religiosity), and provided blood and saliva samples. Cortisol levels and whole genome transcriptional profiling were assessed to identify potential alterations in circadian rhythms and genomic pathways.

Results

Separate Cox regression models, controlling for disease risk category, revealed that CES-D scores (p = 0.05, HR = 1.5, 95% CI for HR: 1.00–2.23) and cortisol slope (p = 0.002; HR = 1.9; 95%CI for HR: 1.27–2.97) were significantly associated with decreased survival. Only cortisol slope and risk category remained significant in the complete model. Functional genomic analyses linked depressive symptoms to increased expression of pro-inflammatory and pro-metastatic genes in circulating leukocytes. 116 transcripts were found to be upregulated by an average of 50% or more in high CES-D patients, and 57 transcripts downregulated by at least 50%. These changes were also found in the tumor in a subset of patients.

Conclusion

These findings identify depressive symptoms as a key predictor of survival in renal cell carcinoma patients with potential links to dysregulation of cortisol and inflammatory biology.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1943274, encodeId=7b3f19432e468, content=<a href='/topic/show?id=eecc6e0131f' target=_blank style='color:#2F92EE;'>#炎症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67013, encryptionId=eecc6e0131f, topicName=炎症基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Sep 25 05:19:00 CST 2012, time=2012-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789464, encodeId=a4d61e89464b2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Mar 19 10:19:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837100, encodeId=f189183e10010, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Dec 27 16:19:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862861, encodeId=fbb21862861d8, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Tue Jan 01 02:19:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984303, encodeId=820d19843033f, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 23 08:19:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289413, encodeId=c148128941374, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347987, encodeId=d4d0134e98763, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]

相关资讯

Transl Psy:血液试验判定青少年抑郁症

近日,西北大学Feinberg医学院研究人员开发出一种血液试验,测量一组遗传标记可以诊断青少年是否抑郁症,相关技术成果发表在Translational Psychiatry杂志上。目前,抑郁症的诊断依赖于患者症状的描述,卫生保健专业人士一直试图解释这些症状。 作者表示:青少年抑郁症的诊断是特别具有挑战性的,部分原因是因为青春期情绪往往波动,在这个年龄段及时、准确地诊断是否患抑郁是很重要的。 在

J Neuro:日研究者发现两种蛋白质结合程度可诊断抑郁症

近日,日本一项新研究发现,分析血液中两种蛋白质的结合程度,就可以诊断是否患上抑郁症。这一发现有望促进开发出用于诊断抑郁症的试剂等,改善抑郁症诊断缺少客观指标,只能采用问诊的局面。 神经突触之间的神经传导物质血清素不足被认为是抑郁症的一个原因。此前研究发现,血清素被过多清除与一种载体蛋白质不分解有关,而这种载体蛋白质必须与一种泛素蛋白质结合才能分解。 名城大学研究人员在美国新一期

J Hypertens:荟萃分析显示抑郁症或增高血压发病危险

  由中国吉林大学白求恩第一医院和中国医学科学院阜外心血管病医院的学者联合开展的一项荟萃分析表明,抑郁症可能是高血压的独立危险因素。在高血压预防和治疗过程中将抑郁症纳入考量范畴非常重要,但尚需进一步研究以排除其他致淆因素的影响。研究于近日在线发表于《高血压杂志》(J Hypertens.)。   长期以来抑郁症被认为与高血压相关,然而抑郁症是否为高血压发病的危险因素目前尚无定论。该研究旨在评估抑

PNAS:脂联素帮助缓解小鼠的抑郁症

近日,科研人员在国际杂志PNAS上报告说,血液循环中的一种代谢激素帮助缓解小鼠的抑郁症症状。此前的研究已经表明了II型糖尿病患者患抑郁症的风险增加。Xin-Yun Lu及其同事检验了一种来自脂肪细胞的激素脂联素 (Adiponectin) ——已知它能控制糖和脂肪的代谢,并且已知它能穿过血脑屏障——是否在抑郁症中起到了作用。这组作者让小鼠在一个既有的实验范式中接受14天的重复的社会压力,在这种环境

Mol.Psychiatry:美研究发现验血可能帮助诊断抑郁症

由美国麻省总医院(MGH)的研究人员等组成的团队报告称,某项分析九个生物标志物水平的检测可准确区分抑郁症患者与对照参与者,而没有显着假阳性结果。相关论文发表在《分子精神病学》(Molecular Psychiatry)杂志上。 “传统上,抑郁症与其他精神障碍的诊断基于患者报告的症状;但该过程的准确性变异非常大,往往取决于进行评估的临床医师的临床经验与资源,”本报告的第一与通讯作者——麻省总医院精

帕金森病患者非运动症状疗法

       一项新的研究报告显示,提高脑中的多巴胺水平可能不足以解决帕金森氏症患者中的非运动性症状,例如抑郁症和疲劳。除了严重的运动损害这一帕金森氏病的标志之外,该病还会引起显著影响生活品质的非运动性症状,诸如抑郁症、疲劳、视幻觉和睡眠问题[Sci Transl Med 4 April 2012: Vol. 4, Issue 128, p. 128ra41